February 15, 2017 / 11:35 PM / in 10 months

FDA approves Valeant's drug to treat plaque psoriasis

Feb 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Valeant Pharmaceuticals International Inc’s Siliq to treat adults with moderate-to-severe plaque psoriasis.

Psoriasis is an autoimmune disorder that occurs more commonly in patients with a family history of the disease, and most often begins in people between the ages of 15 and 35.

Plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales, is the most common form of the disease. (bit.ly/2l9Da9c)

The approval for Siliq injection includes a labeling with boxed warning to mitigate the risk of suicide. Patients treated with Siliq during clinical trials had shown suicidal behavior, the FDA noted. (Reporting by Akankshita Mukhopadhyay in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below